Menu
Recruiting NCT06568289

Lignocaine vs Bupivacaine Infiltration for Postpartum Perineal Pain After Vaginal Delivery With Episiotomy in Primigravidae

No phase Interventional Lignocaine Bupivacaine Postpartum Perineal Pain Vaginal Delivery

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Lignocaine, Bupivacaine.
Who it may be relevant to
Registry conditions: Lignocaine, Bupivacaine, Postpartum Perineal Pain, Vaginal Delivery. Basic parameters: 18 years — 40 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Lignocaine vs Bupivacaine Infiltration for Postpartum Perineal Pain After Vaginal Delivery With Episiotomy in Primigravidae: A Prospective Randomized, Double-Blind, Clinical Trial

Overview

In this study, we will compare the effect and safety of lignocaine versus bupivacaine infiltration for postpartum perineal pain after vaginal delivery with episiotomy in primigravidae.

Detailed description

Episiotomy is the most common procedure used for dilatation of the vaginal opening for giving birth. Although episiotomy is associated with benefits for the mother, it may lead to short term and long-term disabilities, including postpartum perineal pain that is secondary to perineal tearing. The perineal pain experienced due to receiving an episiotomy is severe during the first few days after delivery, and it can lead to limitations in movement and difficulties with urination and defecation.

Bupivacaine is a long-acting local anesthetic that effectively reduces postoperative pain. In practice, bupivacaine is used for infiltration anesthesia, nerve blocks, epidural, and caudal anesthesia. It has a more selective effect on sensory nerve fibers as compared to motor nerve fibers, therefore is preferred in obstetrics.

Lignocaine infiltration, with the presence or absence of epidural anesthesia, is the most frequently employed local anesthetic in ameliorating postpartum perineal pain. It is a rapid-onset amide local anesthetic with a short duration of action lasting up to two hours.

Interventions

  • Drug Lignocaine
    A perineal infiltration of a 5-ml of the drug (100 mg of lignocaine) in the margins of the episiotomy. Careful aspiration before and during injection of the product should be performed to prevent intravascular injection. The entire contents will then be injected slowly at several points of infiltration. All planes will be infiltrated (vagina, muscle, and skin) before episiotomy repair.
  • Drug Bupivacaine
    A perineal infiltration of a 5-ml of the study drug (20 mg of Bupivacaine) in the margins of the episiotomy. Careful aspiration before and during injection of the product should be performed to prevent intravascular injection. The entire contents will then be injected slowly at several points of infiltration. All planes will be infiltrated (vagina, muscle, and skin) before episiotomy repair.

Primary outcome measures

  • Degree of pain [Time frame: 6 hours postoperatively]
Secondary outcome measures (4)
  • The time till first analgesic requirement [Time frame: 6 hours postoperatively]
  • Total analgesics consumption [Time frame: 12 hours postoperatively]
  • Incidence of compilation [Time frame: 6 hours postoperatively]
  • Time of post-operative ambulation [Time frame: 12 hours postoperatively]

Eligibility criteria

Inclusion criteria

  • Primigravidae with the full term undergoing vaginal delivery with episiotomy.
  • Pregnancies and singleton vertex cephalic fetuses.
  • In the active phase of the first stage of labor.

Exclusion criteria

  • Patients with history of drug allergies to study drugs as this will increase the risk of complications.
  • Patients undergoing vaginal delivery under epidural or spinal anesthesia as they will affect post-operative pain and interfere with assessment of efficacy of local infiltration of the study drugs.
  • Evidence of local infection at site of injection as this will interfere with the action of the study drug and will increase the risk of complications.
  • Inability to cooperate as this will affect our assessment.
  • Patient's refusal.
  • Any intraoperative complications that will affect our outcome criteria (bleeding, organ injury) as they will affect patient's vital data and affect our assessment.
  • Neurological comorbidities (chronic pain disorder, chronic systemic disease, neurological disorder, neuropathic pain) as they will need more analgesia.
  • Drug abuse as they will be tolerant to the used analgesics.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Treatment

Study locations

Egypt · 1 center
  • Ain Shams University — Cairo

Identifiers

NCT: NCT06568289 · FMASUMS167/2024

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗